ERINLAR is the very first generic of Ceritinib (DB09063) in Bangladesh. ERINLAR (Ceritinib, DB09063) is a tyrosine kinase inhibitor for oral administration in NSCLC (non-small cell lung cancer). ERINLAR the earliest generics of ZYKADIA (Novartis) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Genvio Pharma Limited, a renowned pharmaceutical company in Bangladesh is manufacturing ERINLAR, the generic of Ceritinib (DB09063) and providing a quality product at an affordable price to the patients globally. ERINLAR, the low cost generic of ZYKADIA (Ceritinib) is most active against ALK. Ceritinib (DB09063) inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. ERINLAR (Ceritinib) 150 mg is available in 28’s pack size. The recommended dose of ERINLAR (Ceritinib, DB09063) is 450 mg orally once daily with food until disease progression or unacceptable toxicity. Worldwide lung cancer is one of most prevalent cancer and treatment of lung cancer is also costly. Genvio Pharma Limited has aimed to provide quality medicine at a reasonable cost that patient can fight against this deadliest cancer and can maintain a healthy life. Each ERiNLAR box contains patient medication information’s so before starting medication please go through the leaflet or download from ERiNLAR (Ceritinib, generic of ZYKADIA) website (www.erinlar.com) Genvio Pharma Limited takes pride in manufacturing quality medicine by adhering to the current Good Manufacturing Practice (cGMP) to meet the international standard. Being one of the top anti-cancer medicine manufacturers in Bangladesh, Genvio Pharma is committed to manufacture better alternatives of research molecules at an affordable price. So Genvio keeps the cost of ZYKADIA generic, ERINLAR comparatively lower than the cost of ZYKADIA for the patient who cannot afford ZYKADIA treatment.